Sign in
Not yet taking people in United StatesPhase 2/3

Testosterone treatment, with or without finasteride, for men with spinal cord injury

Tests testosterone therapy, with or without finasteride, in men with spinal cord injury.

Key facts

Who runs it
VA Office of Research and Development
Where
Aurora, Gainesville, Tampa, and The Bronx, United StatesSee the 4 sites
Trial code
Registry title
Testosterone Therapy With or Without Finasteride After Spinal Cord Injury: TRT-SCI Trial
Status
Not yet recruiting
Phase
Phase 2/3
People taking part
300 people, planned
Starts
1 Oct 2027
Expected to end
31 Mar 2032
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • testosterone cypionate
  • finasteride
  • placebo injection
  • placebo pill
Record updated
4 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for male Veterans with a long-standing, partial spinal cord injury, low testosterone and difficulty walking. It tests testosterone with or without finasteride against placebo.

Age
18 years and older
Sex
Men only
Disease stage
Motor incomplete spinal cord injury (AIS C-D) for >24-months, at spinal level L1 or above, caused by trauma, blood vessel or bone/joint problems. Walking pace ≤1.0 m/s on a 10-meter walk test, or faster but needing a walking aid, brace or showing clear movement problems. At least one sign of low testosterone, such as low energy, low sexual desire or tiredness. Must be medically stable, with a doctor's written approval. Must be able to get care in the Veterans Health Administration (VHA).
Earlier treatment
No testosterone therapy or other drugs that change sex hormones (such as 5-alpha reductase inhibitors, growth hormone, clomiphene, estrogen treatment) in the past 90 days. No bone-building or bone-loss-preventing drugs in the past 180 days.
Biomarker or test result
Low total testosterone (<300 ng/dL) and/or low free testosterone (<4.6 ng/dL). Hematocrit must not be >48%.

Main reasons for not taking part

  • Spinal cord problem present from birth, degenerative spinal disorder, ALS, multiple sclerosis or other nerve disease
  • Current cancer, past prostate or breast cancer, or any cancer in the past 24 months (except treated basal or squamous skin cancer)
  • Major heart or blood vessel event in the last 6 months, or poorly controlled heart disease or blood pressure
  • Major lower-limb fracture in the past 12 months, or past unexplained blood clots
  • Unchecked PSA >4.0 ng/mL (or >3.0 ng/mL with prostate cancer risk factors), or currently trying to have children

The registry criteria, word for word

Show all 37 criteriaShow less

Who can take part

  • Veterans eligible for care within the Veterans Health Administration (VHA)
  • Diagnosis of motor incomplete SCI (AIS C-D) for >24-months involving spinal segment lumbar (L)1 or above from trauma, vascular, or orthopedic pathology
  • Low total testosterone (<300 nanograms/decilliter [ng/dL]) and/or low free testosterone (<4.6 ng/dL)
  • Presence of one or more sign of low testosterone, defined as:; decreased energy; motivation; initiative or self-confidence; increased fatigue or tiredness; reduced sexual desire or activity; decreased spontaneous (e.g., morning) erections or erectile dysfunction; loss of body hair or reduced shaving; feeling sad or blue or having a depressed mood or a persistent low-grade depressive disorder (defined as a score of >3 on the Patient Health Questionnaire [PHQ]-2); hot flashes; fatigue or irritability; poor concentration or memory; mild unexplained (normocytic-normochromic) anemia, defined as hematocrit (HCT) <40%, hemoglobin <13.6 grams/deciliter (g/dL), or red blood cell count <4.5 million/microliter (mcL); sleep disturbances or increased sleepiness; reduced muscle bulk, strength, or physical function; increased body fat or body mass index
  • Presence of motor impairment, defined as self-selected walking pace ≤1.0 meters/second (m/s) on a 10-meter walk test (10mWT), with or without gait devices or braces and with or without assistance from another person, or as self-selected walking pace >1.0 m/s with reliance on a gait device or brace or with highly compensated movement impairment identified by a trained observer
  • Medically stable condition asymptomatic for bladder infection, major decubiti, cardiopulmonary disease, or other significant condition that will interfere with the study
  • Documented approval from a physician verifying medical status

Who cannot take part

  • Major non-cardiovascular surgery (e.g., major abdominal or thoracic procedure) within 90 days before screening or a major surgery scheduled at the time of screening
  • Use of an agent that alters sex-steroid metabolism in the past 90 days, such as: testosterone therapy (TRT), compounded or over-the-counter androgenic hormone or androgen precursor, 5-alpha reductase (5AR) inhibitors, growth hormone, clomiphene, aromatase inhibitors, anti-estrogen or estrogen treatment, or others
  • Use of anti-resorptive or bone anabolic drug therapy in the past 180 days
  • Acute use (>5 days) of any opioid (e.g., oxycodone, hydrocodone) or systemic glucocorticoids >7.5 milligrams (mg)/day prednisone equivalent (e.g., hydrocortisone 30 mg, methylprednisolone 6 mg, or dexamethasone 1.2 mg) in the week before screening, except for men who are taking these for a chronic condition and who are anticipated to continue these for the study duration
  • History of or current congenital spinal cord injury (SCI) (e.g., Chiari malformation, myelomeningocele, intraspinal neoplasm, Friedreich's ataxia) or degenerative spinal disorder (e.g., spinocerebellar degeneration) that may complicate procedures
  • Amyotrophic lateral sclerosis, multiple sclerosis, or other neurologic injury / impairment that may complicate procedures
  • Current cancer diagnosis
  • History of prostate or breast cancer
  • Any diagnosed or treated cancer in the past 24 months, except basal or squamous cell carcinoma of the skin that has been successfully treated
  • Unevaluated circulating prostate-specific antigen (PSA) >4.0 nanograms/milliliter (ng/mL) or >3.0 ng/mL in men with prostate cancer risk factors, including agent orange exposure, first degree relative with prostate cancer, or African American background
  • Any major cardiovascular event in the last 6 months, defined as:; an acute myocardial infarction; any cardiac revascularization procedure including stenting; angioplasty or coronary artery bypass grafting; revascularization of the carotid or middle cerebral artery or procedure to treat critical limb ischemia; hospitalization due to unstable angina; transient ischemic attack; stroke; peripheral vascular disease
  • Any angina that is not controlled on a current medical regimen (Canadian class II, III, or IV)
  • Poorly compensated congestive heart failure (New York Heart Association [NYHA] class III or IV)
  • Poorly controlled hypertension when on medication (consistent systolic BP ≥160 mmHg or diastolic BP ≥100 mmHg)
  • Poorly controlled arrhythmia of any type
  • Severe valvular heart disease
  • History of unprovoked deep venous thrombosis, unprovoked pulmonary embolism, history of recurrent deep venous thrombosis or known thrombophilia
  • Known allergy to any TRT component (e.g., cottonseed oil or other)
  • Any other condition, lab abnormality, therapy, medical or psychiatric condition, or reason that might pose a risk to the participant, make participation not in the person's best interest, confound the study results (e.g., inability to comply with study requirements), make the participant unsuitable to receive a study intervention, or interfere with their ability to participate for the full study duration
  • Liver enzymes (aspartate aminotransferase [AST] or alanine aminotransferase [ALT]) >1.5 times the normal upper limit
  • Severe or end-stage chronic kidney disease defined as eGFR <30 milliliters/minute (mL/min)
  • Involvement in another research study that may influence outcomes
  • Mental state that precludes understanding the protocol
  • Life expectancy <12 months
  • Any major lower-limb fracture in the past 12 months
  • Currently seeking fertility or expected during the study
  • Diagnosed gynecomastia
  • Hematocrit (HCT) >48%
  • Baseline electrocardiogram findings such as left bundle branch block or marked abnormality that precludes serial screening for occult ischemic events
  • Diagnosed, but untreated severe obstructive sleep apnea

Where in United States

  • Rocky Mountain Regional VA Medical Center, Aurora, COAurora, United StatesContact: Joshua F Yarrow, PhD MS BSNot yet recruiting
  • North Florida/South Georgia Veterans Health System, Gainesville, FLGainesville, United StatesContact: Dana Otzel, PhDNot yet recruiting
  • James A. Haley Veterans' Hospital, Tampa, FLTampa, United StatesContact: Kevin White, MDNot yet recruiting
  • James J. Peters VA Medical Center, Bronx, NYThe Bronx, United StatesContact: Christopher Cardozo, MDNot yet recruiting

About the trial

What the trial wants to find out

Spinal cord injury (SCI) results in lower limb muscle loss, bone loss, and high fat mass that impede the recovery of physical function, increase bone fracture risk, and worsen health and quality of life. These deficits result from reduced activity after SCI and may be worsened by low testosterone, which is present in many men with SCI. In older men with low testosterone who do not have SCI, testosterone therapy (TRT) is known to increase muscle mass, muscle strength, and bone mineral density, and to reduce body fat. However, it is not known if TRT is effective in men with SCI. The purposes of this study are to determine the effectiveness of TRT in men who have low testosterone and difficulty walking after chronic motor incomplete SCI and to assess whether a process in the body that changes testosterone to dihydrotestosterone (DHT; another hormone that is stronger than testosterone) impacts the effectiveness of TRT in the impaired lower limbs and in other tissues after SCI. The researchers hypothesize that TRT will improve muscle and bone in the impaired limbs of men with chronic incomplete SCI and reduce fat mass, and that finasteride (a drug that blocks that blocks a process that changes testosterone to DHT) will influence prostate symptoms but not the musculoskeletal or body composition benefits produced by TRT.

The 3 groups in the trial

  • testosterone, placeboTreatment being tested

    Testosterone by intramuscular injection (200 mg/q2wk) and placebo pill orally (5 mg/day)

    Treatment: testosterone cypionate and placebo pill

  • testosterone, finasterideTreatment being tested

    Testosterone by intramuscular injection (200 mg/q2wk) and a finasteride pill orally (5 mg/day)

    Treatment: testosterone cypionate and finasteride

  • placebo treatmentPlacebo, for comparison

    Placebo by intramuscular injection (q2wk) and a placebo pill orally (daily)

    Treatment: placebo injection and placebo pill

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multisite, Double-blind, Randomized Controlled Trial Comparing Body Composition, Muscle, and Bone Changes to TestosteRone Therapy With or Without Finasteride After Spinal Cord Injury: TRT-SCI Trial
Plain-language title
Testosterone treatment, with or without finasteride, for men with spinal cord injuryGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
4 August 2026